MYGN Q3 2017 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$454M

Q3 2017 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$190M+7.2% YoY

Gross Profit

$147M77.4% margin

Operating Income

$87M46.0% margin

Net Income

$81M42.6% margin

EPS (Diluted)

$1.15

QoQ Revenue Growth

-5.1%

Cash Flow

Operating Cash Flow

$24M

Free Cash Flow

$22M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$358M

Stockholders' Equity

$871M

Cash & Equivalents

$88M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$190M	$178M	+7.2%
Gross Profit	$147M	$138M	+7.1%
Operating Income	$87M	$6M	+1309.7%
Net Income	$81M	-$1M	+6858.3%

Revenue Segments

Diagnostics

$179M94%

All Other Segments

$11M6%